Island Pharmaceuticals hits seven-month high on Galidesivir approval for Ebola epidemic
BUZZ-Island Pharmaceuticals hits seven-month high on Galidesivir approval for Ebola epidemic ** Shares of Australia-based Island Pharmaceuticals ILA.AX rise as much as 46.7% to A$0.550, hitting their highest point since December 5, 2025
** The drug repurposing company says it has obtained all government and regulatory approvals for the use of Galidesivir in infected patients during the Bundibugyo Ebola epidemic in Uganda
** Company says the study is the first opportunity for Galidesivir to be prospectively evaluated in patients during an active Ebola outbreak and will help with its clinical development
** Study will also advance Galidesivir towards potential government procurement, biodefence stockpiling and broader commercialisation opportunities as a broad-spectrum antiviral, Island adds
** Stock now up 5.8%, YTD
(Reporting by Shruti Agarwal in Bengaluru)
Recent news on Island Pharmaceuticals
See all newsBrief: Island Pharmaceuticals Says Pivotal Marburg Data Secured For Galidesivir FDA Pathway
Brief: Island Pharmaceuticals Posts Prelim FY Loss Attributable Of A$9.8 Million
Australia's Island Pharmaceuticals rises as company boosts Galidesivir production
Brief: Island Pharmaceuticals Boosts Galidesivir Supply As Ebola Surges
Island Pharmaceuticals hits seven-month high on Galidesivir approval for Ebola epidemic